EU Natural's fertility supplements are unapproved new drugs because website claims treat infertility, PCOS, cancer and other diseases.
What happened
FDA reviewed www.store.eunatural.com in March 2021 and the company's Instagram account, which directs consumers to the store, and found the company takes orders there for CONCEPTION Female Fertility Prenatal and CONCEPTION MEN Male Fertility. FDA found website and social media claims that the products or their ingredients treat or prevent diseases including infertility, PCOS, endometriosis, depression, arthritis, diabetes, cancer, and insomnia. FTC also reviewed the websites in May 2021 and said some efficacy claims may lack competent and reliable scientific evidence.
What FDA found
Website and Instagram claims show the fertility supplements are intended to cure, mitigate, treat, or prevent diseases, so they are drugs under the law.
FD&C Act § 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]The products are unapproved new drugs because they are not generally recognized as safe and effective for the claimed disease uses and lack FDA approval.
FD&C Act §§ 201(p), 505(a), 301(d) [21 U.S.C. §§ 321(p), 355(a), 331(d)]The products are misbranded because they do not bear adequate directions for use by a layperson for diseases that require a licensed practitioner.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]FTC says the disease-related advertising claims may not be supported by competent and reliable scientific evidence.
FTC Act § 5 [15 U.S.C. § 45]
What FDA wants
FDA asks the company to reply in writing within 15 working days describing the specific steps taken to correct the violations and prevent recurrence, including documentation, or to explain why it cannot complete them and when it will. FTC also asks for notice within 15 working days of actions taken to address its concerns.
Who should pay attention
- supplement brands and marketers making fertility or disease-related claims
- retailers and online marketplaces selling fertility supplements
- advertising and social media teams for supplement companies
This is a summary. Read the original letter on fda.gov.